Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  McNeil, Brian K ^a   Sorbellini, Maximiliano ^a   Grubb, Robert L ^b   Apolo, Andrea B ^a   Cecchi, Fabiola ^a   Athauda, Gagani ^a   Cohen, Benjamin ^a   Giubellino, Alessio ^a   Simpson, Haley ^a   Agarwal, Piyush K ^a   Coleman, Jonathan ^a   Getzenberg, Robert H ^c   Netto, George J ^c   Shih, Joanna ^a   Marston Linehan, W ^a   Pinto, Peter A ^a   Bottaro, Donald P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Bladder cancer; HGF receptor; Met; Urine; Urothelial carcinoma

Indexed keywords

CREATININE; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CREATININE URINE LEVEL; CYSTECTOMY; DIAGNOSTIC VALUE; DRUG TARGETING; FALSE NEGATIVE RESULT; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR INVASION; URINALYSIS; AREA UNDER THE CURVE; BLADDER TUMOR; CASE CONTROL STUDY; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SOLUBILITY; URINE; UROTHELIUM;

AREA UNDER CURVE; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; HUMANS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MET; ROC CURVE; SENSITIVITY AND SPECIFICITY; SOLUBILITY; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84925384532     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-199     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
2. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 2001, 19(3):666-675.
3. von der Maase H, Sengelov L, Roberts JT, Sengeløv L, Conte PF, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23(21):4602-4608.
4. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R: The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoecon 2003, 21(18):1315-1330.
5. Cecchi F, Rabe DC, Bottaro DP: Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012, 16(6):553-72.
6. Yamamoto N, Mammadova G, Song RX, Fukami Y, Sato K: Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J Cell Sci 2006, 119(Pt 22):4623-33.
7. Tamatani T, Hattori K, Iyer A, Tamatani K, Oyasu R: Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro. Carcinogenesis 1999, 20(6):957-62.
8. Inui M, Nishi N, Yasumoto A, Takenaka I, Miyanaka H, Matsumoto K, Nakamura T, Wada F: Enhanced gene expression of transforming growth factor-alpha and c-met in rat urinary bladder cancer. Urol Res 1996, 24(1):55-60.
9. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C: Profiling bladder cancer using targeted antibody arrays. Am J Pathol 2006, 168(1):93-103.
10. Cheng HL, Trink B, Tzai TS, Liu HS, Chan SH, Ho CL, Sidransky D, Chow NH: Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 2002, 20(6):1544-1550.
11. Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H: Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and-7 and E-cadherin. Hum Pathol 2009, 40(4):496-504.
12. Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP: c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 2006, 12(14 Pt 1):4154-62.
13. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF: Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178(6):2314-30.
14. Scher H, Bahnson R, Cohen S, Eisenberger M, Herr H, Kozlowski J, Lange P, Montie J, Pollack A, Raghaven D, Richie J, Shipley W: NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology 1998, 12(7A):225-71.
15. Hall RR, Parmar MK, Richards AB, Smith PH: Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994, 308(6923):257-260.
16. Abogunrin F, O'Kane HF, Ruddock MW, Stevenson M, Reid CN, O'Sullivan JM, Anderson NH, O'Rourke D, Duggan B, Lamont JV, Boyd RE, Hamilton P, Nambirajan T, Williamson KE: The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer 2012, 118(10):2641-2650.
17. Strope SA, Ye Z, Hollingsworth JM, Hollenbeck BK: Patterns of care for early stage bladder cancer. Cancer 2010, 116(11):2604-2611.
18. Hollingsworth JM, Zhang Y, Krein SL, Ye Z, Hollenbeck BK: Understanding the variation in treatment intensity among patients with early stage bladder cancer. Cancer 2010, 116(15):3587-3594.
19. Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S: Delay and survival in bladder cancer. BJU Int 2002, 89(9):868-878.
20. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L: Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010, 14(4):1-331. iii-iv.
21. Tetu B: Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009, 22(Suppl 2):S53-59.
22. Margel D, Pevsner-Fischer M, Baniel J, Yossepowitch O, Cohen IR: Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur Urol 2011, 59(1):113-119.
23. Van Rhijn BW, van der Poel HG, van der Kwast TH: Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005, 47(6):736-48.
24. Comperat E, Roupret M, Chartier-Kastler E, Bitker MO, Richard F, Camparo P, Capron F, Cussenot O: Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract. J Urol 2008, 179(3):868-72.
25. Apolo AB, Lee YH, Cecchi F, Agarwal PK, Parnes HL, Khadar K, Summerell A, Gulley JL, Compton K, Figg WD, Dahut WL, Bottaro DP: Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). J Clin Oncol 2013, 31(6):314.
26. Cecchi F, Rabe DC, Bottaro DP: Targeting the HGF/Met Signaling Pathway in Cancer. Eur J Cancer 2010, 46(7):1260-70.
27. Zhu M, Tang R, Doshi S, Oliner KS, Kathman S, Gisleskog PO, Dubey S, Jiang Y, Donehower RC, Iveson T, Loh E: Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer. J Clin Oncol 2012, 30:2535.
28. Spigel DR, Edelman MJ, Mok T, O'Byrne KJ, Paz-Ares L, Yu W, Rittweger K, Thurm HC, on behalf of the MetLUNG Phase III Study Group: The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2012, 30:TPS7616.